# Inception Sciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/inception-sciences

- Industry: Pharmaceuticals
- Headquarters: San Diego, US
- Website: www.inceptionsci.com
- Total disclosed funding: $5M
- Latest round: Series A (Oct 30, 2013)
- Investors on record: 4

## About

Inception Sciences, Inc. is a biotechnology company dedicated to developing innovative therapeutic solutions addressing unmet medical needs through advanced scientific research and collaboration.Founded in 2011 and headquartered in San Diego, US, Inception Sciences, Inc. focuses on creating biotechnology companies that develop novel therapeutic solutions. The company was acquired by Ophthotech Corporation in October 2018, receiving 5.2 million shares of common stock. Led by a team with extensive experience, the founder has a history of establishing successful ventures in the biotech sector. Notably, Inception Sciences has completed 2 deals, with its latest funding being a Series A round led by Versant Ventures, raising USD 5.00 mn, and achieving a current valuation of USD 17.51 mn.Inception Therapeutics specializes in forming innovative biotechnology companies that develop therapeutic solutions for unmet medical needs. The company’s core offerings leverage scientific breakthroughs and technology platforms across various therapeutic areas. With advanced wetlab capabilities, Inception collaborates with Versant Ventures to introduce transformative biopharmaceutical products, primarily targeting healthcare providers, patients with specific conditions, and pharmaceutical partners in North America and Europe.Inception Therapeutics generates revenue through strategic partnerships and collaborations within the biotechnology sector. Operating on a B2B model, the company provides proprietary technologies and drug development capabilities to pharmaceutical companies and research institutions. Revenues are driven by licensing agreements, R&D partnerships, and milestone payments related to successful drug candidate advancements, though specific pricing plans remain undisclosed. The company’s financial performance is expected to be bolstered by its flagship therapeutic developments and ongoing industry collaborations.Inception Sciences plans to utilize recent funding to advance its therapeutic developments and expand its market reach. The company aims to introduce new products targeting specific medical conditions and enhance its presence in key geographic regions, particularly within North America and Europe by the end of 2025. The strategic acquisition by Ophthotech Corporation in October 2018 is expected to further facilitate these growth initiatives.

## Funding rounds

- Series A, Oct 30, 2013, $5M — Versant Ventures, Fonds de Solidarité des Travailleurs du Québec, Celgene, Inserm Transfert Initiative

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A
- Fonds de Solidarité des Travailleurs du Québec — Series A
- Celgene — Series A
- Inserm Transfert Initiative (https://capitalatlas.ai/funds/inserm-transfert-initiative) — Series A